<ul>
<li>2 个理由说明 Absci 可能是 AI 生物科技的未来，以及 1 个风险</li>
</ul>
<p>Absci Corporation（NASDAQ:ABSI - 免费报告）- HC Wainwright 的股票研究人员在 5 月 11 日星期一发布的研究报告中提高了对 Absci 2026 年第三季度每股收益的预期。HC Wainwright 分析师 S. Ramakanth 现在预计该公司本季度每股收益为（$0.22），高于之前预测的（$0.23）。市场普遍预计 Absci 当前全年的每股收益为（$0.83）。HC Wainwright 还对 Absci 2026 年第四季度的收益进行了预测，预计为每股（$0.22），2026 财年的收益为每股（$0.84），2027 年第一季度的收益为每股（$0.12），2027 年第二季度的收益为每股（$0.16），2027 年第三季度的收益为每股$0.12，2027 年第四季度的收益为每股（$0.18），2028 财年的收益为每股$0.11，以及 2029 财年的收益为每股$0.09。</p>
<p>Absci（NASDAQ:ABSI - 获取免费报告）在 5 月 7 日星期四发布了其收益结果。该公司报告本季度每股收益为（$0.19），超出分析师普遍预期的（$0.20）$0.01。Absci 的净利润率为负的 6450.76%，股本回报率为负的 66.32%。该公司在本季度的收入为 22 万美元，而市场普遍预期为 139 万美元。</p>
<ul>
<li>现在哪个医疗保健股票是最佳买入？</li>
</ul>
<p>其他几家研究公司最近也对 ABSI 发表了评论。Truist Financial 在 5 月 8 日星期五的报告中将 Absci 的目标价从$9.00 上调至$11.00，并给予该股票 “买入” 评级。Weiss Ratings 在 4 月 20 日星期一的报告中重申了对 Absci 的 “卖出（d-）” 评级。最后，Needham &amp; Company LLC 在 3 月 25 日星期三的报告中重申了 “买入” 评级，并对 Absci 的目标价设定为$7.00。四位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为$7.58。</p>
<p><strong>阅读我们关于 Absci 的最新报告</strong></p>
<h2>Absci 股票下跌 7.3%</h2>
<p>Absci 股票在星期三开盘价为$5.36。Absci 的 12 个月低点为$2.24，12 个月高点为$6.72。该公司的 50 日移动平均价格为$3.47，200 日移动平均价格为$3.34。该公司的市值为 8.3565 亿美元，市盈率为-6.46，贝塔值为 2.36。</p>
<h2>Absci 的机构交易</h2>
<p>几家机构投资者和对冲基金最近对 ABSI 的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Absci 的持仓提高了 279.4%。AQR Capital Management LLC 现在拥有 55,538 股该公司的股票，价值 139,000 美元，此前在上个季度购买了 40,901 股。高盛集团在第一季度将其在 Absci 的持仓提高了 17.5%。高盛集团现在拥有 314,858 股该公司的股票，价值 790,000 美元，此前在上个季度购买了 46,975 股。Woodline Partners LP 在第一季度将其在 Absci 的持仓提高了 32.9%。Woodline Partners LP 现在拥有 1,391,245 股该公司的股票，价值 3,492,000 美元，此前在上个季度购买了 344,270 股。Geode Capital Management LLC 在第二季度将其在 Absci 的持仓提高了 22.5%。Geode Capital Management LLC 现在拥有 2,445,450 股该公司的股票，价值 6,286,000 美元，此前在上个季度购买了 448,984 股。最后，Creative Planning 在第二季度将其在 Absci 的持仓提高了 145.4%。Creative Planning 现在拥有 46,882 股该公司的股票，价值 120,000 美元，此前在上个季度购买了 27,775 股。对冲基金和其他机构投资者持有该公司 52.05% 的股票。</p>
<h2>Absci 的内部交易</h2>
<p>在其他新闻中，内部人士 Andreas Busch 在 3 月 12 日星期四以每股平均成本$2.29 购买了 100,000 股该股票，总交易额为$229,000.00。购买后，该内部人士直接持有 421,446 股该公司的股票，价值$965,111.34。此交易代表其持仓增加了 31.11%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站获取。10.49% 的股票由公司内部人士持有。</p>
<h2>Absci 新闻汇总</h2>
<p>以下是本周影响 Absci 的主要新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 提高了对 Absci 的长期收益展望，包括对 2028 财年和 2029 财年每股收益的上调，暗示盈利前景随着时间的推移而改善。Absci 分析师估计更新</li>
<li>积极情绪：该公司还上调了对 2030 财年每股收益的预期，强化了 Absci 如果执行改善可能在未来几年产生可观收益的观点。Absci 分析师估计更新</li>
<li>中性情绪：HC Wainwright 对近期的估计进行了适度修订，包括对 2026 年第三季度和第四季度每股收益的略微上调，但预计该公司在至少 2027 年之前仍将出现亏损。Absci 分析师估计更新</li>
<li>消极情绪：即使在修订后的估计中，市场共识预期仍指向全年亏损，而 Absci 最近的季度结果显示收入远低于预期，给股票带来压力。Absci 收益结果</li>
</ul>
<h2>Absci 公司简介</h2>
<p>（获取免费报告）</p>
<p>Absci Corporation NASDAQ: ABSI 是一家生物技术公司，利用机器学习、合成生物学和自动化技术加速基于蛋白质的治疗药物的发现和开发。该公司的综合药物创制平台（Integrated Drug Creation®，IDC®）旨在以传统生物制药发现方法无法匹敌的速度和规模识别和生产新型抗体和酶候选物。Absci 与制药和生物技术合作伙伴合作，生成、筛选和优化用于广泛治疗应用的蛋白质分子。</p>
<p>Absci 的核心产品是其端到端的发现引擎，该引擎结合了专有算法、高通量实验室自动化和深度学习框架。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，优于 Absci</li>
<li>Ally Financial 回归基础，投资者在关注</li>
<li>Navitas 因印度交易突破，验证高功率 AI 转型</li>
<li>海军催化剂点燃 Odysight 的增长引擎</li>
<li>AST SpaceMobile 因银河第一季度业绩不佳暴跌：垂直整合能拯救 SpaceX 竞争对手吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Absci 吗？</h2>
<p>在考虑 Absci 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Absci 并不在名单上。</p>
<p>虽然 Absci 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABSI

<p>HC Wainwright 将 Absci Corporation (NASDAQ:ABSI) 2026 年第三季度每股收益（EPS）预估从（$0.23）上调至（$0.22）。全年共识预估为每股（$0.83）。Absci 在第一季度报告的每股收益为（$0.19），超出预期。分析师对该股票的评级不一，整体评级为 “适度买入”，目标价为 $7.58。Absci 的股票目前下跌 7.3%，交易价格为 $5.36，市值为 $8.3565 亿。内部人士 Andreas Busch 最近将其持股增加了 31.11%</p>

<ul>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>2 个理由说明 Absci 可能是 AI 生物科技的未来，以及 1 个风险</li>
</ul>
</div><p>Absci Corporation (NASDAQ:ABSI - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Absci in a research report issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.22) per share for the quarter, up from their prior forecast of ($0.23). The consensus estimate for Absci's current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Absci's Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at $0.12 EPS, Q4 2027 earnings at ($0.18) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.09 EPS.</p>
<div class="lb-trans"><p>Absci Corporation（NASDAQ:ABSI - 免费报告）- HC Wainwright 的股票研究人员在 5 月 11 日星期一发布的研究报告中提高了对 Absci 2026 年第三季度每股收益的预期。HC Wainwright 分析师 S. Ramakanth 现在预计该公司本季度每股收益为（$0.22），高于之前预测的（$0.23）。市场普遍预计 Absci 当前全年的每股收益为（$0.83）。HC Wainwright 还对 Absci 2026 年第四季度的收益进行了预测，预计为每股（$0.22），2026 财年的收益为每股（$0.84），2027 年第一季度的收益为每股（$0.12），2027 年第二季度的收益为每股（$0.16），2027 年第三季度的收益为每股$0.12，2027 年第四季度的收益为每股（$0.18），2028 财年的收益为每股$0.11，以及 2029 财年的收益为每股$0.09。</p>
</div><p>Absci (NASDAQ:ABSI - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.01. Absci had a negative net margin of 6,450.76% and a negative return on equity of 66.32%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $1.39 million.</p>
<div class="lb-trans"><p>Absci（NASDAQ:ABSI - 获取免费报告）在 5 月 7 日星期四发布了其收益结果。该公司报告本季度每股收益为（$0.19），超出分析师普遍预期的（$0.20）$0.01。Absci 的净利润率为负的 6450.76%，股本回报率为负的 66.32%。该公司在本季度的收入为 22 万美元，而市场普遍预期为 139 万美元。</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p>Several other research firms also recently commented on ABSI. Truist Financial raised their price objective on shares of Absci from $9.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, May 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Absci in a report on Monday, April 20th. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $7.00 price objective on shares of Absci in a report on Wednesday, March 25th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.58.</p>
<div class="lb-trans"><p>其他几家研究公司最近也对 ABSI 发表了评论。Truist Financial 在 5 月 8 日星期五的报告中将 Absci 的目标价从$9.00 上调至$11.00，并给予该股票 “买入” 评级。Weiss Ratings 在 4 月 20 日星期一的报告中重申了对 Absci 的 “卖出（d-）” 评级。最后，Needham &amp; Company LLC 在 3 月 25 日星期三的报告中重申了 “买入” 评级，并对 Absci 的目标价设定为$7.00。四位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为$7.58。</p>
</div><p><strong>Read Our Latest Report on Absci</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Absci 的最新报告</strong></p>
</div><h2>Absci Stock Down 7.3%</h2>
<div class="lb-trans"><h2>Absci 股票下跌 7.3%</h2>
</div><p>Absci stock opened at $5.36 on Wednesday. Absci has a twelve month low of $2.24 and a twelve month high of $6.72. The firm has a 50 day moving average price of $3.47 and a 200-day moving average price of $3.34. The company has a market capitalization of $835.65 million, a P/E ratio of -6.46 and a beta of 2.36.</p>
<div class="lb-trans"><p>Absci 股票在星期三开盘价为$5.36。Absci 的 12 个月低点为$2.24，12 个月高点为$6.72。该公司的 50 日移动平均价格为$3.47，200 日移动平均价格为$3.34。该公司的市值为 8.3565 亿美元，市盈率为-6.46，贝塔值为 2.36。</p>
</div><h2>Institutional Trading of Absci</h2>
<div class="lb-trans"><h2>Absci 的机构交易</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in ABSI. AQR Capital Management LLC raised its position in shares of Absci by 279.4% during the 1st quarter. AQR Capital Management LLC now owns 55,538 shares of the company's stock valued at $139,000 after buying an additional 40,901 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Absci by 17.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 314,858 shares of the company's stock valued at $790,000 after buying an additional 46,975 shares in the last quarter. Woodline Partners LP raised its position in shares of Absci by 32.9% during the 1st quarter. Woodline Partners LP now owns 1,391,245 shares of the company's stock valued at $3,492,000 after buying an additional 344,270 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Absci by 22.5% during the 2nd quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company's stock valued at $6,286,000 after buying an additional 448,984 shares in the last quarter. Finally, Creative Planning raised its position in shares of Absci by 145.4% during the 2nd quarter. Creative Planning now owns 46,882 shares of the company's stock valued at $120,000 after buying an additional 27,775 shares in the last quarter. Hedge funds and other institutional investors own 52.05% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对 ABSI 的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Absci 的持仓提高了 279.4%。AQR Capital Management LLC 现在拥有 55,538 股该公司的股票，价值 139,000 美元，此前在上个季度购买了 40,901 股。高盛集团在第一季度将其在 Absci 的持仓提高了 17.5%。高盛集团现在拥有 314,858 股该公司的股票，价值 790,000 美元，此前在上个季度购买了 46,975 股。Woodline Partners LP 在第一季度将其在 Absci 的持仓提高了 32.9%。Woodline Partners LP 现在拥有 1,391,245 股该公司的股票，价值 3,492,000 美元，此前在上个季度购买了 344,270 股。Geode Capital Management LLC 在第二季度将其在 Absci 的持仓提高了 22.5%。Geode Capital Management LLC 现在拥有 2,445,450 股该公司的股票，价值 6,286,000 美元，此前在上个季度购买了 448,984 股。最后，Creative Planning 在第二季度将其在 Absci 的持仓提高了 145.4%。Creative Planning 现在拥有 46,882 股该公司的股票，价值 120,000 美元，此前在上个季度购买了 27,775 股。对冲基金和其他机构投资者持有该公司 52.05% 的股票。</p>
</div><h2>Insider Transactions at Absci</h2>
<div class="lb-trans"><h2>Absci 的内部交易</h2>
</div><p>In other news, insider Andreas Busch bought 100,000 shares of the stock in a transaction on Thursday, March 12th. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $229,000.00. Following the purchase, the insider directly owned 421,446 shares of the company's stock, valued at $965,111.34. This trade represents a 31.11% increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 10.49% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Andreas Busch 在 3 月 12 日星期四以每股平均成本$2.29 购买了 100,000 股该股票，总交易额为$229,000.00。购买后，该内部人士直接持有 421,446 股该公司的股票，价值$965,111.34。此交易代表其持仓增加了 31.11%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站获取。10.49% 的股票由公司内部人士持有。</p>
</div><h2>Absci News Roundup</h2>
<div class="lb-trans"><h2>Absci 新闻汇总</h2>
</div><p>Here are the key news stories impacting Absci this week:</p>
<div class="lb-trans"><p>以下是本周影响 Absci 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright raised its longer-term earnings outlook for Absci, including higher FY2028 and FY2029 EPS estimates, suggesting improving profitability prospects over time. Absci analyst estimate updates</li>
<li>Positive Sentiment: The firm also nudged up its FY2030 EPS estimate, reinforcing the view that Absci could generate meaningful earnings in the out-years if execution improves. Absci analyst estimate updates</li>
<li>Neutral Sentiment: HC Wainwright also made modest revisions to near-term estimates, including slightly better Q3 2026 and Q4 2026 EPS forecasts, but the company is still expected to post losses through at least 2027. Absci analyst estimate updates</li>
<li>Negative Sentiment: Even with the revised estimates, consensus expectations still point to a full-year loss, and Absci’s recent quarterly results showed very low revenue versus expectations, keeping pressure on the stock. Absci earnings results</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 提高了对 Absci 的长期收益展望，包括对 2028 财年和 2029 财年每股收益的上调，暗示盈利前景随着时间的推移而改善。Absci 分析师估计更新</li>
<li>积极情绪：该公司还上调了对 2030 财年每股收益的预期，强化了 Absci 如果执行改善可能在未来几年产生可观收益的观点。Absci 分析师估计更新</li>
<li>中性情绪：HC Wainwright 对近期的估计进行了适度修订，包括对 2026 年第三季度和第四季度每股收益的略微上调，但预计该公司在至少 2027 年之前仍将出现亏损。Absci 分析师估计更新</li>
<li>消极情绪：即使在修订后的估计中，市场共识预期仍指向全年亏损，而 Absci 最近的季度结果显示收入远低于预期，给股票带来压力。Absci 收益结果</li>
</ul>
</div><h2>Absci Company Profile</h2>
<div class="lb-trans"><h2>Absci 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Absci Corporation NASDAQ: ABSI is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company's Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.</p>
<div class="lb-trans"><p>Absci Corporation NASDAQ: ABSI 是一家生物技术公司，利用机器学习、合成生物学和自动化技术加速基于蛋白质的治疗药物的发现和开发。该公司的综合药物创制平台（Integrated Drug Creation®，IDC®）旨在以传统生物制药发现方法无法匹敌的速度和规模识别和生产新型抗体和酶候选物。Absci 与制药和生物技术合作伙伴合作，生成、筛选和优化用于广泛治疗应用的蛋白质分子。</p>
</div><p>The core of Absci's offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.</p>
<div class="lb-trans"><p>Absci 的核心产品是其端到端的发现引擎，该引擎结合了专有算法、高通量实验室自动化和深度学习框架。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Absci</li>
<li>Ally Financial Is Back to Basics—And Investors Are Watching</li>
<li>Navitas Breaks Out on India Deal, Validating High-Power AI Pivot</li>
<li>Navy Catalyst Ignites Odysight’s Growth Engine</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，优于 Absci</li>
<li>Ally Financial 回归基础，投资者在关注</li>
<li>Navitas 因印度交易突破，验证高功率 AI 转型</li>
<li>海军催化剂点燃 Odysight 的增长引擎</li>
<li>AST SpaceMobile 因银河第一季度业绩不佳暴跌：垂直整合能拯救 SpaceX 竞争对手吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABSI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Absci Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Absci 吗？</h2>
</div><p>Before you consider Absci, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Absci 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Absci 并不在名单上。</p>
</div><p>While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Absci 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Absci 第三季度的收益预期持乐观态度